Safety and Efficacy Analysis of Everolimus in Metastatic Breast Cancer and Metastatic Renal Cell Carcinoma Patient

Abstract

Breast cancers is a heterogeneous group of neoplasm originating from the epithelial cells lining the milk ducts and are most common malignancies. Breast cancer causes approximately 18% of all cancer deaths in women worldwide. Renal cell carcinoma is a cancer in which malignant cells form in tubules of the kidney. Prevalence of Kidney cancer is 35% in elderly people aged 75 and over. Renal cell carcinoma is rare in people under 50 and it is diagnosed more often in men than women. It is responsible for 4.3% of malignancies with increased risk of disease after the age of 60 years. It is documented that endocrine therapy is the standard first line treatment in advance breast cancer. But intrinsic and acquired resistance to endocrine therapy remains a common feature that limits the success of this therapeutic strategy. In metastatic renal cell carcinoma, sunitinib and sorafenib are first line therapy. But MRCC patients develop resistance to these VEGF-TKIs and progression free survival (PFS) decreases. mTOR inhibitor (Everolimus) affords clinical benefits with increased PFS and is a better option for MBC &MRCC patients if the adverse effects are managed well. Keeping these facts in mind, it was considered worthwhile to undertake a study to analyse the safety and efficacy of Everolimus in metastatic breast cancer and metastatic renal cell carcinoma patients. Objective To analyse safety and efficacy of Everolimus and observe progression free survival (PFS), Overall survival (OS), Response rate (RR).